Prolactin-growth factor crosstalk reduces mammary estrogen responsiveness despite elevated ERα expression

American Journal of Pathology

Volumn 174, Issue 3, 2009, Pages 1065-1074

  Arendt, Lisa M ^a   Grafwallner Huseth, Tara L ^a   Schuler, Linda A ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR ALPHA; GROWTH FACTOR; LIPOCALIN; NEU RELATED LIPOCALIN; PROGESTERONE; PROGESTERONE RECEPTOR; PROLACTIN; PROTEIN KINASE B; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSGENIC MOUSE;

EID: 62549090119     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.080719     Document Type: Article

References (68)

1. The Endogenous Hormones and Breast Cancer Collaborative Group: Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002, 94:606-616
2. Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, Hankinson SE: Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 2006, 98:1406-1415
3. Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principle results from the women's health initiative randomized controlled trial. JAMA 2002, 288:321-333
4. Samuel JC, Ollila DW: Prophylaxis and screening options: recommendations for young women with BRCA mutations. Breast Dis 2005, 23:31-35
5. Sainsbury R: Ovarian ablation in the adjuvant treatment of premenopausal and perimenopausal breast cancer. Br J Surg 2003, 90:517-526
6. Normanno N, Di Maio M, De Maio E, De Luca A, de Matteis A, Giordano A, Perrone F: Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 2005, 12:721-747
7. Oakes SR, Rogers RL, Naylor MJ, Ormandy CJ: Prolactin regulation of mammary gland development. J Mammary Gland Biol Neoplasia 2008, 13:13-28
8. Vonderhaar BK: Prolactin involvement in breast cancer. Endocr Relat Cancer 1999, 6:389-404
9. Clevenger CV, Furth PA, Hankinson SE, Schuler LA: Role of prolactin in mammary carcinoma. Endocr Rev 2003, 24:1-27
10. Goffin V, Bernichtein S, Touraine P, Kelly PA: Development and potential clinical uses of human prolactin receptor antagonists. Endocr Rev 2005, 26:400-422
11. Tworoger SS, Hankinson SE: Prolactin and breast cancer risk. Cancer Lett 2006, 243:160-169
12. McHale K, Tomaszewski JE, Puthiyaveettil R, Livolsi VA, Clevenger CV: Altered expression of prolactin receptor-associated signaling proteins in human breast carcinoma. Mod Pathol 2008
13. Frasor J, Gibori G: Prolactin regulation of estrogen receptor expression. Trends Endocrinol Metab 2003, 14:118-123
14. Kleis-SanFrancisco S, Hewetson A, Chilton BS: Prolactin augments progesterone-dependent uteroglobin gene expression by modulating promoter-binding proteins. Mol Endocrinol 1993, 7:214-223
15. Muldoon TG: Prolactin mediation of estrogen-induced changes in mammary tissue estrogen and progesterone receptors. Endocrinology 1987, 121:141-149
16. Edery M, Imagawa W, Larson L, Nandi S: Regulation of estrogen and progesterone receptor levels in mouse mammary epithelial cells grown in serum-free collagen gel cultures. Endocrinology 1985, 116:105-112
17. Gutzman JH, Miller KK, Schuler LA: Endogenous hPRL and not exogenous hPRL induces ERa and PRLR expression and increases estrogen responsiveness in breast cancer cells. J Steroid Biochem Mol Biol 2004, 88:69-77
18. Gutzman JH, Nikolai SE, Rugowski DE, Watters JJ, Schuler LA: Prolactin and estrogen enhance the activity of Activating Protein-1 in breast cancer cells: role of ERK1/2-mediated signals to c-fos. Mol Endocrinol 2005, 19:1765-1778
19. Eferl R, Wagner EF: AP-1: a double-edged sword in tumorigenesis. Nature Rev Cancer 2003, 3:859-868
20. Shaulian E, Karin M: AP-1 as a regulator of cell life and death. Nat Cell Biol 2002, 4:E131-E136
21. Rose-Hellekant TA, Arendt LM, Schroeder MD, Gilchrist K, Sandgren EP, Schuler LA: Prolactin induces ERα-positive and ERα-negative mammary cancer in transgenic mice. Oncogene 2003, 22:4664-4674
22. Yarden Y: The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001, 37:S3-S8
23. Holbro T, Civenni G, Hynes NE: The ErbB receptors and their role in cancer progression. Exp Cell Res 2003, 284:99-110
24. Booth BW, Smith GH: Roles of transforming growth factor-alpha in mammary development and disease. Growth Factors 2007, 25:227-235
25. De Bortoli M, Dati C: Hormonal regulation of type I receptor tyrosine kinase expression in the mammary gland. J Mammary Gland Biol Neoplasia 1997, 2:175-185
26. Nicholson RI, McClelland RA, Gee JMW, Manning DL, Cannon P, Robertson JFR, Ellis IO, Blamey RW: Transforming growth-factor-alpha and endocrine sensitivity in breast cancer. Cancer Res 1994, 54:1684-1689
27. Bieche I, Onody P, Tozlu S, Driouch K, Vidaud M, Lidereau R: Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer 2003, 106:758-765
28. Panico L, D'Antonio A, Salvatore G, Mezza E, Tortora G, De Laurentiis M, De Placido S, Giordano T, Merino M, Salomon DS, Mullick WJ, Pettinato G, Schnitt SJ, Bianco AR, Ciardiello F: Differential immuno-histochemical detection of transforming growth factor alpha, amphiregulin and CRIPTO in human normal and malignant breast tissues. Int J Cancer 1996, 65:51-56
29. Arendt LM, Rose-Hellekant TA, Sandgren EP, Schuler LA: Prolactin potentiates TGFα induction of mammary neoplasia in transgenic mice. Am J Pathol 2006, 168:1365-1374
30. Rose-Hellekant TA, Schroeder MD, Brockman JL, Zhdankin O, Bolstad R, Chen KS, Gould MN, Schuler LA, Sandgren EP: Estrogen receptor positive mammary tumorigenesis in TGFα transgenic mice progresses with progesterone receptor loss. Oncogene 2007, 26:5238-5246
31. Guzman RC, Yang J, Rajkumar L, Thordarson G, Chen XY, Nandi S: Hormonal prevention of breast cancer: Mimicking the protective effect of pregnancy. Proc Natl Acad Sci USA 1999, 96:2520-2525
32. Medina D, Kittrell FS, Shepard A, Contreras A, Rosen JM, Lydon J: Hormone dependence in premalignant mammary progression. Cancer Res 2003, 63:1067-1072
33. Schroeder MD, Symowicz J, Schuler LA: Prolactin modulates cell cycle regulators in mammary tumor epithelial cells. Mol Endocrinol 2002, 16:45-57
34. Shyamala G, Chou YC, Louie SG, Guzman RC, Smith GH, Nandi S: Cellular expression of estrogen and progesterone receptors in mammary glands: regulation by hormones, development and aging. J Steroid Biochem Mol Biol 2002, 80:137-148
35. Anderson E, Clarke RB, Howell A: Estrogen receptor in mammary gland physiology. Contemporary Endocrinology: Endocrine Oncology. Edited by Ethier SP. Totowa NY, Humana Press, Inc, 2000. pp. 1-16
36. Clarke RB, Howell A, Potten CS, Anderson E: Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 1997, 57:4987-4991
37. Kirkegaard T, Witton CJ, McGlynn LM, Tovey SM, Dunne B, Lyon A, Bartlett JM: AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 2005, 207:139-146
38. Tokunaga E, Kataoka A, Kimura Y, Oki E, Mashino K, Nishida K, Koga T, Morita M, Kakeji Y, Baba H, Ohno S, Maehara Y: The association between Akt activation and resistance to hormone therapy in metastatic breast cancer. Eur J Cancer 2006, 42:629-635
39. Murphy LO, Smith S, Chen RH, Fingar DC, Blenis J: Molecular interpretation of ERK signal duration by immediate early gene products. Nat Cell Biol 2002, 4:556-564
40. Huang Y, Li X, Jiang J, Frank SJ: Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells. Oncogene 2006, 25:7565-7576
41. Coleman KM, Smith CL: Intracellular signaling pathways: nongenomic actions of estrogens and ligand-independent activation of estrogen receptors. Front Biosci 2001, 6:D1379-D1391
42. Shupnik MA: Crosstalk between steroid receptors and the c-Srcreceptor tyrosine kinase pathways: implications for cell proliferation. Oncogene 2004, 23:7979-7989
43. Hovey RC, Trott JF, Ginsburg E, Goldhar A, Sasaki MM, Fountain SJ, Sundararajan K, Vonderhaar BK: Transcriptional and spatiotemporal regulation of prolactin receptor mRNA and cooperativity with progesterone receptor function during ductal branch growth in the mammary gland. Dev Dyn 2001, 222:192-205
44. Mueller SO, Clark JA, Myers PH, Korach KS: Mammary gland development in adult mice requires epithelial and stromal estrogen receptor α. Endocrinology 2002, 143:2357-2365
45. Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM: Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 2005, 97:1254-1261
46. Cui X, Schiff R, Arpino G, Osborne CK, Lee AV: Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 2005, 23:7721-7735
47. Martin MB, Franke TF, Stoica GE, Chambon P, Katzenellenbogen BS, Stoica BA, McLemore MS, Olivo SE, Stoica A: A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. Endocrinology 2000, 141:4503-4511
48. Cui X, Zhang P, Deng W, Oesterreich S, Lu Y, Mills GB, Lee AV: Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 2003, 17:575-588
49. Ross RK, Paganini-Hill A, Wan PC, Pike MC: Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000, 92:328-332
50. Saji S, Jensen EV, Nilsson S, Rylander T, Warner M, Gustafsson JA: Estrogen receptors alpha and beta in the rodent mammary gland. Proc Natl Acad Sci USA 2000, 97:337-342
51. Aupperlee MD, Smith KT, Kariagina A, Haslam SZ: Progesterone receptor isoforms A and B: temporal and spatial differences in expression during murine mammary gland development. Endocrinology 2005, 146:3577-3588
52. Haslam SZ, Shyamala G: Effect of oestradiol on progesterone receptors in normal mammary glands and its relationship with lactation. Biochem J 1979, 182:127-131
53. Shyamala G, Ferenczy A: The nonresponsiveness of lactating mammary gland to estradiol. Endocrinology 1982, 110:1249-1256
54. Wu RC, Smith CL, O'Malley BW: Transcriptional regulation by steroid receptor coactivator phosphorylation. Endocr Rev 2005, 26:393-399
55. Lannigan DA: Estrogen receptor phosphorylation. Steroids 2003, 68:1-9
56. Torres-Arzayus MI, De Mora JF, Yuan J, Vazquez F, Bronson R, Rue M, Sellers WR, Brown M: High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 2004, 6:263-274
57. Gutzman JH, Rugowski DE, Schroeder MD, Watters JJ, Schuler LA: Multiple kinase cascades mediate prolactin signals to activating protein-1 in breast cancer cells. Mol Endocrinol 2004, 18:3064-3075
58. Xiao ZQ, Li J, Majumdar AP: Regulation of TGF-alpha-induced activation of AP-1 in the aging gastric mucosa. Am J Physiol Gastrointest Liver Physiol 2003, 285:G396-G403
59. Petz LN, Ziegler YS, Loven MA, Nardulli AM: Estrogen receptor α and activating protein-1 mediate estrogen responsiveness of the progesterone receptor gene in MCF-7 breast cancer cells. Endocrinology 2002, 143:4583-4591
60. Petz LN, Ziegler YS, Schultz JR, Nardulli AM: Fos and Jun inhibit estrogen-induced transcription of the human progesterone receptor gene through an activator protein-1 site. Mol Endocrinol 2004, 18:521-532
61. Lange CA, Shen T, Horwitz KB: Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc Natl Acad Sci USA 2000, 97:1032-1037
62. Song RX, Zhang Z, Santen RJ: Estrogen rapid action via protein complex formation involving ERalpha and Src. Trends Endocrinol Metab 2005, 16:347-353
63. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P: Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 2000, 74:311-317
64. O'Brien JE, Peterson TJ, Tong MH, Lee EJ, Pfaff LE, Hewitt SC, Korach KS, Weiss J, Jameson JL: Estrogen-induced proliferation of uterine epithelial cells is independent of estrogen receptor alpha binding to classical estrogen response elements. J Biol Chem 2006, 281:26683-26692
65. Shen Q, Zhang Y, Uray IP, Hill JL, Kim HT, Lu C, Young MR, Gunther EJ, Hilsenbeck SG, Chodosh LA, Colburn NH, Brown PH: The AP-1 transcription factor regulates postnatal mammary gland development. Dev Biol 2006, 295:589-603
66. Silva CM: Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 2004, 23:8017-8023
67. Stoecklin E, Wissler M, Schaetzle D, Pfitzner E, Groner B: Interactions in the transcriptional regulation exerted by Stat5 and by members of the steroid hormone receptor family. J Steroid Biochem Mol Biol 1999, 69:195-204
68. Osborne CK, Yochmowitz MG, Knight WA, III, McGuire WL: The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980, 46:2884-2888